
The FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.
Catch up on recent regulatory decisions by the FDA in oncology, including actions in lung, hematologic, genitourinary, and gastrointestinal cancers.
November was accompanied by a slew of FDA approvals across various tumor types, including multiple hematologic and lung cancers, along with an approval each in genitourinary and gastrointestinal cancers.






